Rapid Onset of Action on Nasal Symptoms and Ocular Symptom Improvement With Olopatadine/Mometasone Combination Nasal Spray in Patients With Seasonal Allergic Rhinitis

Rationale In two randomized double-blind studies, twice-daily GSP301 nasal spray-a fixed-dose combination of olopatadine hydrochloride and mometasone furoate-significantly improved reflective total nasal symptom score (rTNSS) versus placebo (primary endpoint; presented elsewhere). Methods In each study (study 1 [NCT02631551]; study 2 [NCT02870205]), patients >=12 years with seasonal allergic rhinitis (SAR) were equally randomized to GSP301 (olopatadine 665μg/mometasone 25μg BID), olopatadine (665μg BID), mometasone (25μg BID), or placebo for 14 days.